November 18, 2013
VBL Therapeutics to host a Satellite Symposium on VB‐111, A Novel Drug for Recurrent GBM at the 2013 Scientific Meeting of the Society for Neuro-Oncology

VBL Therapeutics today announced that Prof. Dror Harats, M.D., Chief Executive Officer, will host a Satellite Symposium at the 2013 Scientific Meeting of the Society for Neuro-Oncology (SNO) on Friday, November 22, 2013 at 12:00 p.m. at the Marriot Marquis hotel, Yerba Buena Ballroom 10‐13 in San Francisco.


Prof. Harats will host a panel that will also include Dr. Andrew Brenner, from the University of Texas Health Science Center at San Antonio, Dr. Yael Cohen, MD, VP Clinical Development at VBL Therapeutics and Dr. Deborah Blumenthal from the Tel‐Aviv Sourasky Medical Center. The panel is expected to highlight VBL therapeutics’ proprietary Vascular Targeting System (VTS™) platform that has yielded VB‐111, a first‐in‐class, highly‐targeted, novel anti‐angiogenic biological agent for the treatment of cancer.

VB-111 is given as a simple IV infusion and acts like a “biological knife” to cut the vasculature feeding the tumor. With promising Phase 2 clinical data showing encouraging effects on Overall Survival in recurrent Glioblastoma Multiforme (rGBM) and multiple cases of objective response, VBL is planning ahead towards a VB-111 pivotal trial in rGBM. Orphan drug status for GBM was awarded to VB-111 in the US and in Europe. VB-111 is also evaluated in multi-dose Phase 2 clinical trials for differentiated thyroid cancer and ovarian cancer.

About VB-111

VB-111 is a novel IV-administered anti angiogenic agent that utilizes VTS™, VBL’s proprietary platform technology to target endothelial cells in the tumor vasculature for cancer therapy. VB-111 contains a non-replicating adenovector, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene. The modified promoter specifically targets the expression of the Fas-Chimera transgene to angiogenic tumor blood vessels, leading to their apoptosis. VB-111 is the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial.

VB-111 has successfully completed a Phase I/II “all comers” clinical trial, which demonstrated multiple cases of objective tumor response and disease control and excellent safety and tolerability. VB-111 has been advanced into tumor specific, repeat-dose trials in glioblastoma multiforme, thyroid cancer and ovarian cancer.

About VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, an anti-angiogenic agent for cancer, which is currently in multiple Phase 2 clinical trials. In addition, VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201 is the company’s lead candidate from this program, currently in Phase 2 clinical development in patients with psoriasis or inflammatory bowel disease. Both programs target multibillion dollar markets with unmet need for safe and well-tolerated treatments, and provide differentiation from current or proposed treatments.

Founded in 2000, VBL is based in Tel Aviv, Israel. The company has more than 120 granted patents and more than 150 applications pending.

For more information on the company, please visit